{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-008044","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.282668+00:00","generated_at":"2026-05-16T21:20:42.089081+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia","bullets":["BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.","CEO Sam Tan to serve as CEO of Fidelion; BGLC gets two board seats.","VitaGuard MRD test detects ctDNA at 0.02% VAF, ~95% cfDNA recovery, no tissue needed.","Exclusive ASEAN commercialization rights; initial focus on Singapore and Malaysia.","Conditions include IP license agreement; other definitive agreements not yet executed."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-008044","json":"https://secwatch.observer/filing/0001477932-25-008044.json","markdown":"https://secwatch.observer/filing/0001477932-25-008044.md","text":"https://secwatch.observer/filing/0001477932-25-008044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225008044/0001477932-25-008044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225008044/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:20:42.089081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"146be0bfe0cd45fe05dadac329289db7587ef6fb","claim":"BioNexus Gene Lab Corp issued restricted shares representing 19.9% of its outstanding common stock of common stock to Fidelion Diagnostics Pte. Ltd..","evidence_excerpt":"In connection with the SSSA, upon completion the Company will issue restricted shares representing 19.9% of its outstanding common stock to Fidelion as consideration for the Company’s subscription of Fidelion shares.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225008044/0001477932-25-008044-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"restricted shares representing 19.9% of its outstanding common stock"},{"label":"Purchaser","value":"Fidelion Diagnostics Pte. Ltd."}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}